Momentous Data For Oxford/Novavax Malaria Vaccine
First To Achieve WHO's 75% Efficacy Goal
Executive Summary
A year to the day since the first dose of its COVID-19 vaccine was given, Oxford University's Jenner Institute has unveiled stellar findings from a Phase IIb trial of its malaria vaccine.
You may also be interested in...
Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise
Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.
GSK’s Malaria Vaccine To Be Made By Bharat Biotech For WHO
GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.